Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.

International journal of oncology

Volumn 26, Issue 4, 2005, Pages 1025-1031

  Kim, Ryungsa ^a   Tanabe, Kazuaki ^a   Emi, Manabu ^a   Uchida, Yoko ^a   Osaki, Akihiko ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN BCL 2; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NICK END LABELING; PATHOLOGY; PHOSPHORYLATION; PREMENOPAUSE; SURVIVAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; FEMALE; HUMANS; IN SITU NICK-END LABELING; MIDDLE AGED; PHOSPHORYLATION; PREMENOPAUSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; SURVIVAL; TAMOXIFEN; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 22844431741     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.26.4.1025     Document Type: Article

References (0)